Table 4. Prevalence and Extent of Intraprostatic Inflammation* in Cases with Progression from No/Very Low or Low LUTS and Controls, Placebo Arm, PCPT.
| Progression from no/very low LUTS** | Progression from low LUTS*** | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Controls | Cases | P | Controls | Cases | P | |
| All men | 45 | 46 | 46 | 46 | ||
| At least one biopsy core with inflammation**** | 64 | 65 | 0.9 | 78 | 52 | 0.009 |
| Mean of the percentage of biopsy cores with inflammation | 32 | 30 | 0.8 | 37 | 33 | 0.6 |
| Mean of the mean of percentage of tissue area with inflammation | ||||||
| Overall | 2.7 | 2.5 | 0.8 | 3.6 | 5.3 | 0.3 |
| In men with at least one biopsy core with inflammation | 4.1 | 3.9 | 0.8 | 4.6 | 10.1 | 0.06 |
| In men without prostate cancer | ||||||
| At least one biopsy core with inflammation | 61 | 67 | 0.6 | 77 | 54 | 0.04 |
| Mean of the percentage of biopsy cores with inflammation | 29 | 30 | 0.9 | 35 | 35 | 0.9 |
| Mean of the mean of percentage of tissue area with inflammation | ||||||
| Overall | 2.4 | 2.3 | 0.9 | 2.9 | 5.8 | 0.2 |
| In men with at least one biopsy core with inflammation | 3.9 | 3.5 | 0.7 | 3.8 | 10.7 | 0.05 |
| In men without diabetes | ||||||
| At least one biopsy core with inflammation | 68 | 65 | 0.8 | 80 | 55 | 0.01 |
| Mean of the percentage of biopsy cores with inflammation | 34 | 30 | 0.5 | 39 | 35 | 0.6 |
| Mean of the mean of percentage of tissue area with inflammation | ||||||
| Overall | 2.9 | 2.5 | 0.6 | 3.7 | 5.5 | 0.3 |
| In men with at least one biopsy core with inflammation | 4.3 | 3.9 | 0.6 | 4.6 | 10.1 | 0.06 |
Assessed in 3 cores of 6-10 obtained largely from the peripheral zone from transrectal ultrasound guided biopsies.
Controls had IPSS < 8 at baseline and baseline to biopsy slope < 25th percentile. Cases had IPSS < 8 at baseline and baseline to biopsy slope >75th percentile.
Controls had IPSS = 8-14 at baseline and baseline to biopsy slope < 25th percentile. Cases had IPSS = 8-14 at baseline and baseline to biopsy slope >75th percentile.
After multivariable adjustment for age; race; diabetes history; daily intake (continuous) of energy, polyunsaturated fat, total fat, total protein, red meat; number of alcoholic beverages per day (continuous); aspirin use: progression from no/very low to higher LUTS: controls 64%, cases 66%; P = 0.9; progression from low to higher LUTS: controls 78%, cases 53%, P = 0.01).